Leerink Partners analyst Michael Cherny has reiterated their bullish stance on MCK stock, giving a Buy rating on January 27.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Michael Cherny has given his Buy rating due to a combination of factors surrounding McKesson’s strategic acquisition of PRISM Vision Holdings. This move is seen as a logical and beneficial expansion of McKesson’s existing Management Services Organization (MSO) platform, particularly in the specialty ophthalmology sector. The acquisition is expected to not only fit well within McKesson’s US Oncology segment but also extend its reach into other high-growth specialty areas.
The deal is anticipated to provide immediate financial benefits, with an estimated contribution to earnings per share (EPS) that is both significant and accretive over the next several years. This aligns with the broader industry trend of vertical integration and strategic roll-ups, which have historically supported the success of specialty platforms. Given these strategic and financial advantages, Cherny reaffirms a positive outlook for McKesson, supporting the Buy recommendation.
In another report released on January 27, Evercore ISI also maintained a Buy rating on the stock with a $650.00 price target.